Overall, the differences we found in the tumor genomic landscape suggest that treatment strategies and the development of new therapeutics for advanced HR+/HER2- BC may need to be adapted for patients previously treated with CDK4/6i. This evidence concerns the gene ERBB2 and neoplasm.